Haitong International released a research report on April 15 stating that it gave Tebao Biotech (688278.SH) an superior rating to the market, and the target price was 89.20 yuan. The main reasons for the rating include: 1) continued revenue growth driven rapid revenue growth; 2) continuous revenue expansion led to rapid cost-side dilution, compounding a one-time increase in gross margin, making the profit growth rate higher than revenue growth; 3) the continuous expansion of clinical treatment space for slow hepatitis B, which is optimistic that Pegbin will continue to be released in the future; 4) other long-term recombinant protein products have entered the harvest period, driving the second growth curve. (Mainichi Keizai Shimbun)
海通国际4月15日发布研报称，给予特宝生物（688278.SH）优于大市评级，目标价格为89.20元。评级理由主要包括：1）派格宾持续放量带动公司收入快速增长；2）收入规模持续扩大带动费用端快速摊薄，叠加毛利率的一次性提升，使得利润增速高于收入增速；3）慢乙肝临床治愈空间不断扩大，看好派格宾未来持续放量；4）其他长效重组蛋白产品进入收获期，拉动第二成长曲线。（每日经济新闻）
Haitong International released a research report on April 15 stating that it gave Tebao Biotech (688278.SH) an superior rating to the market, and the target price was 89.20 yuan. The main reasons for the rating include: 1) continued revenue growth driven
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.